Philip Larsen
Chief Executive Officer Antag Therapeutics
Philip Larsen is the CEO of SixPeaks Bio, a company focused on next-generation therapies for obesity and metabolic diseases. With over two decades of executive experience in global pharmaceutical R&D, he has led therapeutic innovation from discovery through clinical proof-of-concept. His previous roles include Senior Vice President and Global Head of Research & Early Development at Bayer Pharmaceuticals, where he oversaw therapeutic innovation. Philip holds an MD and PhD from the University of Copenhagen and has a strong background in neuroscience. His expertise spans obesity therapeutics, incretin biology, and metabolic target validation, underpinned by a track record of advancing molecules from bench to bedside.
Seminars
- GIPR antagonism sensitizes GLP-1 receptor agonists and amylin agonists to deliver more profound weight loss especially in clinical conditions with increased insulin resistance
- GIPR antagonism improves cardiovascular risk and shows promise of delivering healthy weight loss
